Table 2.
Kinetics of SARS-CoV-2 IgG Spike titre at T1 ant T2, respectively 21 days and 5–6 months after the second vaccine dose in HC and MS subjects treated with different DMTs.
| DMTs | SARS-CoV-2 IgG Spike titre (U/mL) | p-value | |
|---|---|---|---|
| Median (IQR) T1 | Median (IQR) T2 | ||
| Healthy Controls | 1087 (640.3 – 1542) | 533.8 (366.4 – 1008) | 0.003 |
| Interferon-β 1a | 1909 (1073 – 2758) | 566.6 (427.5 – 1182) | <0.0001 |
| Dimethyl fumarate | 1587 (767.7 – 3472) | 694.6 (438.3 – 1103) | 0.009 |
| Teriflunomide | 1312 (288.4 – 1920) | 507.8 (278.7 – 1514) | 0.38 |
| Natalizumab | 735.1 (351.3 – 2151) | 456.4 (198.6 – 1156) | 0.002 |
| Glatiramer Acetate | 446.5 (417.7 – 3034) | 232.9 (167.5 – 440.4) | 0.015 |
| Cladribine | 468.2 (65.5 – 1021) | 246.5 (145.3 – 363.3) | 0.31 |
| Fingolimod | 20.6 (5.9 – 456.3) | 70.7 (13.2 – 157.3) | 0.94 |
| Ocrelizumab | 1.2 (0.4 – 119.4) | 0.4 (0.4 – 4.3) | 0.10 |
Wilcoxon two-tailed test was performed to compare SARS-CoV-2 IgG Spike titre at T2 and T1 in HC and MS subjects treated with different DMTs. Data are reported as median and IQR at T1 and T2. A p-value less than 0.05 was considered statistically significant.
DMTs: Disease modifying therapies; IQR: Interquartile range.